Pfizer is here to help your patients access their prescribed TUKYSA tablets

Seagen Secure® offers patient support
Co-Pay Assistance
Eligible, commercially insured patients may pay as little as $0 per month for TUKYSA. Limits, terms, and conditions apply.* Patients may receive up to $10,000 per product in savings annually. There are no income requirements to enroll.
Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.
Voucher Program
30-day free trial offer to help patients new to TUKYSA initiate therapy. Limits, terms, and conditions apply.† Please see below for details.
Please reach out to your Pfizer sales representative for more details. If you don't yet have a representative, please call 866-992-5965.
How to fill a TUKYSA prescription
SPECIALTY PHARMACIES
- Biologics
- Onco360
IN-OFFICE DISPENSERS
(MEDICALLY INTEGRATED DISPENSARIES)
(MEDICALLY INTEGRATED DISPENSARIES)
IDN SPECIALTY PHARMACIES + HOSPITAL PHARMACIES
IDN = integrated delivery network.
Physician practices can obtain TUKYSA from one of the following specialty distributors:
-
ASD HEALTHCARECall 800-746-6273 | Fax 800-547-9413Visit asdhealthcare.com
-
CARDINAL HEALTH SPECIALTY DISTRIBUTIONCall 855-740-1871 | Fax 888-345-4916Visit cardinalhealth.com
-
MCKESSON PLASMA AND BIOLOGICS, LLCCall 877-625-2566 | Fax 888-752-7626Visit mckesson.com
-
MCKESSON SPECIALTY HEALTHCall 800-482-6700 | Fax 800-800-5673
-
ONCOLOGY SUPPLYCall 800-633-7555 | Fax 800-248-8205Visit oncologysupply.com
TUKYSA® (tucatinib) dosage
strengths and counts:






These specialty pharmacies are authorized to distribute TUKYSA:
Keep current on TUKYSA® (tucatinib). Register for email updates.
Important Safety Information
Warnings and Precautions
- Diarrhea: TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death. If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA. In MOUNTAINEER, when TUKYSA was given in combination with trastuzumab, diarrhea occurred in 64% of patients, including Grade 3 (3.5%), Grade 2 (10%), and Grade 1 (50%).
- Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA. In MOUNTAINEER, 6% of patients had a bilirubin increase > 3 × ULN (Grade ≥3), 6% had an AST increase > 5 × ULN, and 4.7% had an ALT increase > 5 × ULN. Hepatotoxicity led to dose reduction of TUKYSA in 3.5% of patients and discontinuation of TUKYSA in 2.3% of patients.
- Embryo-Fetal Toxicity: TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.
Adverse Reactions
Serious adverse reactions occurred in 22% of patients; the most common (in ≥2% of patients) were intestinal obstruction (7%), urinary tract infection (3.5%), pneumonia, abdominal pain, and rectal perforation (2.3% each).
Adverse reactions leading to permanent discontinuation of TUKYSA occurred in 6% of patients; the most common (in ≥2% of patients) was increased ALT (2.3%). Adverse reactions leading to dosage interruption occurred in 23% of patients; the most common (in ≥3% of patients) were increased ALT and diarrhea (3.5% each). Adverse reactions leading to dose reduction occurred in 9% of patients; the most common (in ≥2% of patients) were increased ALT and diarrhea (2.3% each).
The most common adverse reactions (≥20%) in patients treated with TUKYSA and trastuzumab were diarrhea, fatigue, rash, nausea, abdominal pain, infusion-related reactions, and pyrexia.
Other adverse reactions (<10%) include epistaxis (7%), weight decreased (7%), oropharyngeal pain (5%), oral dysesthesia (1%), and stomatitis (1%).
Lab Abnormalities
In MOUNTAINEER, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased lymphocytes, decreased sodium, increased AST, and increased bilirubin.
The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible in 87% of patients with values outside normal lab limits upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.
Drug Interactions
- Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA with a CYP3A substrate, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.
Use in Specific Populations
- Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
- Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.
REF-T1K1163
Indication
TUKYSA is indicated in combination with trastuzumab for the treatment
of adult patients with RAS wild-type, HER2-positive
unresectable or metastatic colorectal cancer that has progressed
following treatment with fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
Please see full Prescribing Information.
Important Safety Information
Important Safety Information and Indication
Indication
Warnings and Precautions
Warnings and Precautions
-
Diarrhea:
TUKYSA can cause severe diarrhea including dehydration,
hypotension, acute kidney injury, and death. If diarrhea occurs,
administer antidiarrheal treatment as clinically indicated.
Perform diagnostic tests as clinically indicated to exclude
other causes of diarrhea. Based on the severity of the diarrhea,
interrupt dose, then dose reduce or permanently discontinue
TUKYSA.
In MOUNTAINEER, when TUKYSA was given in combination with trastuzumab, diarrhea occurred in 64% of patients, including Grade 3 (3.5%), Grade 2 (10%), and Grade 1 (50%). - Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA. In MOUNTAINEER, 6% of patients had a bilirubin increase > 3 × ULN (Grade ≥3), 6% had an AST increase > 5 × ULN, and 4.7% had an ALT increase > 5 × ULN. Hepatotoxicity led to dose reduction of TUKYSA in 3.5% of patients and discontinuation of TUKYSA in 2.3% of patients.
-
Embryo-Fetal Toxicity:
TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.
Adverse Reactions
Serious adverse reactions occurred in 22% of patients; the most common (in ≥2% of patients) were intestinal obstruction (7%), urinary tract infection (3.5%), pneumonia, abdominal pain, and rectal perforation (2.3% each).
Adverse reactions leading to permanent discontinuation of TUKYSA occurred in 6% of patients; the most common (in ≥2% of patients) was increased ALT (2.3%). Adverse reactions leading to dosage interruption occurred in 23% of patients; the most common (in ≥3% of patients) were increased ALT and diarrhea (3.5% each). Adverse reactions leading to dose reduction occurred in 9% of patients; the most common (in ≥2% of patients) were increased ALT and diarrhea (2.3% each).
The most common adverse reactions (≥20%) in patients treated with TUKYSA and trastuzumab were diarrhea, fatigue, rash, nausea, abdominal pain, infusion-related reactions, and pyrexia.
Other adverse reactions (<10%) include epistaxis (7%), weight decreased (7%), oropharyngeal pain (5%), oral dysesthesia (1%), and stomatitis (1%).
Lab Abnormalities
In MOUNTAINEER, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased lymphocytes, decreased sodium, increased AST, and increased bilirubin.
The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible in 87% of patients with values outside normal lab limits upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.
Drug Interactions
- Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA with a CYP3A substrate, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.
Use in Specific Populations
- Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
- Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.
REF-T1K1163
Indication
TUKYSA is indicated in combination with trastuzumab for the
treatment of adult patients with RAS wild-type,
HER2-positive unresectable or metastatic colorectal cancer that
has progressed following treatment with fluoropyrimidine-,
oxaliplatin-, and irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on
tumor response rate and durability of response. Continued approval
for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trials.
Please see full Prescribing Information.
TUKYSA is indicated in combination with trastuzumab for the treatment
of adult patients with RAS wild-type, HER2-positive
unresectable or metastatic colorectal cancer that has progressed
following treatment with fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on tumor
response rate and durability of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trials.
Please see full Prescribing Information.
Terms and conditions for the TUKYSA® (tucatinib) tablets trial voucher program: 1. Voucher is valid for one 30-day trial. Only patients who are new to TUKYSA therapy are eligible to use the voucher. 2. By redeeming the voucher, you certify that you are not currently taking TUKYSA and have not previously taken TUKYSA. 3. The voucher may not be transferred, sold, purchased, traded, or counterfeited. 4. An original voucher and a valid prescription must be presented to the pharmacy. 5. The voucher will be accepted only at participating specialty pharmacies that are authorized to dispense TUKYSA. 6. You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP). 7. You must be 18 years of age or older to redeem the voucher. 8. The voucher is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance. 9. The voucher is not valid where prohibited by law. 10. The voucher cannot be combined with any other savings, free trial or similar offer for the specified prescription. The voucher should not be combined with samples for the specified prescription. 11. The free trial voucher is not health insurance. The free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription. 12. Offer good only in the United States and Puerto Rico. 13. No purchase is necessary. 14. No membership fees. 15. Patients have no obligation to continue to use TUKYSA. 16. Pfizer reserves the right to rescind, revoke, or amend this offer without notice.